Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer

Fig. 2

The association of LRP1B mutation at baseline with clinical outcomes of ICIs plus chemotherapy. A Objective response rate (ORR) (left) and durable clinical benefit (DCB) rate (right) between patients with LRP1B mutant and wild type. B The association of LRP1B mutation with PD-L1, tumor size at baseline, CRP level, and bTMB, respectively. Fisher’s exact test was used for statistical analysis. C Multivariate COX analysis of LRP1B mutation, bTMB, PD-L1, CRP, and tumor size at baseline. Mut, mutant; WT, wild-type; ORR, objective response rate; DCB, durable clinical benefit; CRP, C-reactive protein; bTMB, blood-based tumor mutational burden

Back to article page